CD34⁺ Cell Mobilization, Autograft Cellular Composition and Outcome in Mantle Cell Lymphoma Patients.

ABSTRACT:

Backgound

Autologous stem cell transplantation (ASCT) is a standard treatment in transplant-eligible mantle cell lymphoma (MCL) patients after first-line chemoimmunotherapy.

Study design and methods

This prospective multicenter study evaluated the impact of CD34⁺ cell mobilization and graft cellular composition analyzed by flow cytometry on hematologic recovery and outcome in 42 MCL patients.

Results

During CD34⁺ cell mobilization, a higher blood CD34⁺ cell count (>30 × 10⁶/L) was associated with improved overall survival (median not reached [NR] vs. 57 months, p = 0.04). The use of plerixafor did not impact outcome. Higher number of viable cryopreserved graft CD34⁺ cells (>3.0 × 10⁶/kg) was asso

SUBMITTER: Turunen AS 

PROVIDER: S-EPMC10601603 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature